To evaluate the immunohistochemical characterization of CK5/6 and CK17 and whether the expression level of the two markers was correlated with clinical outcome or pathological feature in triple negative (ER-, PR-, HER-2-) patients with breast cancer.
Methods and study design
We carried out an immunohistochemical assay for CK5/6 and CK17 markers on formalin-fixed invasive carcinoma samples from 112 patients who were diagnosed between 2000 and 2002. All of them had an immunohistochemical triple negative status and follow-up information available.
Results
Of the 112 patients characterized by triple negative immunohistochemical status, 82 (73.2%) were disease free with no relapse or metastasis. In total, CK5/6 and CK17 were both determined positive in 33.9% (38/112) of the 112 tumor samples, and 46.4% (52/112) were regarded as positive for CK5/6 or CK17. The Kaplan-Meier curve showed that positive staining for CK5/6, CK17, or CK which means CK5/6 positive or CK17 positive, was associated with worse disease-free survival (P = 0.020, P = 0.032, P = 0.003), and positive staining for CK5/6 or CK was associated with worse overall survival (P = 0.027, P = 0.015). When we considered 91 patients whose pathological type was invasive ductal carcinoma, we found that there was also an association between CK5/6 or CK17 immunostaining and high grade (P = 0.030). In addition, these two markers were also associated with axillary lymph node status (P = 0.044). The Cox regression multiple-factor analysis showed that pathological stage, grade and expression of CK were the factors affecting both disease-free and overall survival, whereas age and menopausal status were independent factors affecting disease-free and overall survival, respectively.
Conclusions
Positive staining for CK5/6 or CK17 was associated with a worse prognosis, high tumor grade and positive axillary lymph nodes.
van't VeerL.J., DaiH., van de VijverM.J., HeY.D., HartA.A., MaoM., PeterseH.L., van der KooyK., MartonM.J., WitteveenA.T., SchreiberG.J., KerkhovenR.M., RobertsC., LinsleyP.S., BernardsR., FriendS.H.: Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415: 530–536, 2002.
2.
SorlieT., TibshiraniR., ParkerJ., HastieT., MarronJ.S., NobelA., DengS., JohnsenH., PesichR., GeislerS., DemeterJ., PerouC.M., LonningP.E., BrownP.O., Borresen-DaleA.L., BotsteinD.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100: 8418–8423, 2003.
3.
van de VijverM.J., HeY.D., van't VeerL.J., DaiH., HartA.A., VoskuilD.W., SchreiberG.J., PeterseJ.L., RobertsC., MartonM.J., ParrishM., AtsmaD., WitteveenA., GlasA., DelahayeL., van der VeldeT., BartelinkH., RodenhuisS., RutgersE.T., FriendS.H., BernardsR.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med, 347: 1999–2009, 2002.
4.
HuangE., ChengS.H., DressmanH., PittmanJ., TsouM.H., HorngC.F., BildA., IversenE.S., LiaoM., ChenC.M., WestM., NevinsJ.R., HuangA.T.: Gene expression predictors of breast cancer outcomes. Lancet, 361: 1590–1596, 2003.
5.
SotiriouC., NeoS.Y., McShaneL.M., KornE.L., LongP.M., JazaeriA., MartiatP., FoxS.B., HarrisA.L., LiuE.T.: Breast cancer classification and prognosis based on gene expression profiles from a population based study. Proc Natl Acad Sci USA, 100: 10393–10398, 2003.
6.
PerouC.M., JeffreyS.S., van de RijnM., ReesC.A., EisenM.B., RossD.T., PergamenschikovA., WilliamsC.F., ZhuS.X., LeeJ.C., LashkariD., ShalonD., BrownP.O., BotsteinD.: Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA, 96: 9212–9217, 1999.
7.
PerouC.M., SorlieT., EisenM.B., van de RijnM., JeffreyS.S., ReesC.A., PollackJ.R., RossD.T., JohnsenH., AkslenL.A., FlugeO., PergamenschikovA., WilliamsC., ZhuS.X., LonningP.E., Borresen-DaleA.L., BrownP.O., BotsteinD.: Molecular portraits of human breast tumours. Nature, 406: 747–752, 2000.
DentR., TrudeauM., PritchardK.I., HannaW.M., KahnH.K., SawkaC.A., LickleyL.A., RawlinsonE., SunP., NarodS.A.: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13: 4429–4434, 2007.
Abd El-RehimD.M., PinderS.E., PaishC.E., BellJ., BlameyR.W., RobertsonJ.F., NicholsonR.I., EllisI.O.: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol, 203: 661–671, 2004.
12.
van de RijnM., PerouC.M., TibshiraniR., HaasP., KallioniemiO., KononenJ., TorhorstJ., SauterG., ZuberM., KochliO.R., MrossF., DieterichH., SeitzR., RossD., BotsteinD., BrownP.: Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol, 161: 1991–1996, 2002.
13.
NielsenT.O., HsuF.D., JensenK., CheangM., KaracaG., HuZ., Hernandez-BoussardT., LivasyC., CowanD., DresslerL., AkslenL.A., RagazJ., GownA.M., GilksC.B., van de RijnM., PerouC.M.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10: 5367–5374, 2004.
14.
ElstonC.W., EllisI.O.: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19: 403–410, 1991.
15.
SaezR.A., McGuireW.L., ClarkG.M.: Prognostic factors in breast cancer. Semin Surg Oncol, 5: 102–110, 1989.
16.
RobertsonJ.: Prognostic and response markers in the management of breast cancer. Cancer treatment Rev, 23(Suppl 1): S41–S48, 1997.
17.
LivasyC.A., KaracaG., NandaR., TretiakovaM.S., OlopadeO.I., MooreD.T., PerouC.M.: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 19: 264–271, 2006.
18.
PotemskiP., KusinskaR., WatalaC., PluciennikE., BednarekA.K., KordekR.: Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology, 69: 478–485, 2005.
19.
GustersonB.A., RossD.T., HeathV.J., SteinT.: Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res, 7: 143–148, 2005.
20.
DairkeeS.H., PuettL., HackettA.J.: Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst, 80: 691–695, 1988.
21.
MalzahnK., MitzeM., ThoenesM.: Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch, 433: 119–129, 1998.
22.
DairkeeS.H., MayallB.H., SmithH.S., HackettA.J.: Monoclonal marker that predicts early recurrence of breast cancer. Lancet, 1: 514, 1987.
23.
GuelsteinV.I., TchypyshevaT.A., ErmilovaV.D., LitvinovaL.V., TroyanovskyS.M., BannikovG.A.: Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int J Cancer, 42: 147–153, 1988.
24.
CareyL.A., PerouC.M., LivasyC.A., DresslerL.G., CowanD., ConwayK., KaracaG., TroesterM.A., TseC.K., EdmistonS., DemingS.L., GeradtsJ., CheangM.C., NielsenT.O., MoormanP.G., EarpH.S., MillikanR.C.: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295: 2492–2502, 2006.
25.
Abd El-RehimD.M., BallG., PinderS.E., RakhaE., PaishC., RobertsonJ.F., MacmillanD., BlameyR.W., EllisI.O.: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer, confirming recent cDNA expression analyses. Int J Cancer, 116: 340–350, 2005.
26.
RakhaE.A., PuttiT.C., Abd El-RehimD.M., PaishC., GreenA.R., PoweD.G., LeeA.H., RobertsonJ.F., EllisI.O.: Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol, 208: 495–506, 2006.
27.
KorschingE., PackeisenJ., AgelopoulosK., EisenacherM., VossR., IsolaJ., van DiestP.J., BrandtB., BoeckerW., BuergerH.: Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest, 82: 1525–1533, 2002.
28.
MatosI., DuflothR., AlvarengaM., ZeferinoL.C., SchmittF.: p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch, 447: 688–694, 2005.
29.
FoulkesW.D., BrunetJ.S., StefanssonI.M., StraumeO., ChappuisP.O., BéginL.R., HamelN., GoffinJ.R., WongN., TrudelM., KapustaL., PorterP., AkslenL.A.: The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res, 64: 830–835, 2004.
30.
RakhaE.A., El-SayedM.E., GreenA.R., LeeA.H., RobertsonJ.F., EllisI.O.: Prognostic markers in triple-negative breast cancer. Cancer, 109: 25–32, 2007.
31.
TischkowitzM., BrunetJ.S., BéginL.R., HuntsmanD.G., CheangM.C., AkslenL.A., NielsenT.O., FoulkesW.D.: Use of immunohistochemical markers can refine prognosis in triple-negative breast cancer. BMC Cancer, 7: 134, 2007.
